Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis

The Janus kinase inhibitor tofacitinib is currently being investigated as a disease-modifying agent in rheumatoid arthritis (RA). We investigated the in-vivo effects of tofacitinib treatment for 4 weeks on elevated circulating acute-phase serum amyloid (SAA) levels in 14 Japanese patients with RA. S...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Migita, K, Izumi, Y, Jiuchi, Y, Kozuru, H, Kawahara, C, Izumi, M, Sakai, T, Nakamura, M, Motokawa, S, Nakamura, T, Kawakami, A
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3892412/
https://ncbi.nlm.nih.gov/pubmed/24665995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados